课题基金 / 基金详情

Core-001

Core-001
核心001
批准号:
10782243
负责人:
Richard Thomas Wyatt
金额:
$139.64万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-02-04 至 2026-01-31
关键词:

项目摘要

项目成果

Richard Thomas Wyatt的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Nonhuman primates (NHP) specifically, rhesus macaques (RMs), are a key animal model in investigating prevention strategies of HIV infection. This animal model of simian immunodeficiency virus (SIV)/ simian-human immunodeficiency virus (SHIV) infection has been utilized to elucidate both basic concepts in immunization and evaluate clinically relevant prevention approaches. RMs are ideal for investigating the humoral and cellular responses generated by HIV candidate immunizations and the impact on acquisition of infection. NHP studies require extensive coordination, expertise, personnel, and infrastructure. Therefore, the NHP Core (Core B) will support this HIVRAD research team by executing the four preclinical RM immunization studies proposed in Project 1. The animals will receive a variety of novel candidate immunogens and vaccine strategies. Their immune responses will be monitored throughout the study via collection of blood and tissues. Dependent upon those results, potentially, a select few animals will undergo viral challenge with SHIV to test the efficacy of the immunizations. Core B will support the success of this research program by 1) ensuring the adherence to regulatory approvals and procedures necessary for NHP research; 2) coordination of animal selection, assignment, substance administration and sample collection; 3) proper storage and shipment of all samples to the collaborating PIs and Cores; 4) coordination of data collection, analysis, and distribution; 5) and ensuring the monitoring of animal health over the course of the studies. This NHP core will work closely with the collaborators for the vaccine and challenge studies and will participate actively in the scientific mission of this HIVRAD. Further, it will ensure that all NHP research is integrated with the goals of this proposal and the evolving needs of the studies. Core B is led by Dr. Guido Silvestri, who has >20 years of experience leading NHP research projects involving complex study design and intervention, specifically, he has executed a large number of collaborative pre-clinical vaccine trials. During this research he was essential in investigating and developing novel sample collection techniques, such as lymph node fine needle aspirates, for the continued monitoring of germinal center responses during longitudinal studies. Core B will be based at Yerkes National Primate Research Center (YNPRC) at Emory University, this NIH-funded primate research center possesses all the proper animal resources and state-of-the-art veterinarian care expertise necessary to support the proposed work. As an integral part of this research program, the NHP Core will provide critical support to achieve the shared objectives of evaluating these proposed promising novel pre-clinical vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
  • 批准号:
    10339439
  • 项目类别:
  • 资助金额:
    $342.0万
  • 财政年份:
    2021
  • 负责人:
    Richard Thomas Wyatt
  • 依托单位:
Core-002
  • 批准号:
    10794904
  • 项目类别:
  • 资助金额:
    $113.05万
  • 财政年份:
    2021
  • 负责人:
    Richard Thomas Wyatt
  • 依托单位:
Project 1
  • 批准号:
    10339443
  • 项目类别:
  • 资助金额:
    $115.59万
  • 财政年份:
    2021
  • 负责人:
    Richard Thomas Wyatt
  • 依托单位:
Admin Core
  • 批准号:
    10339440
  • 项目类别:
  • 资助金额:
    $21.4万
  • 财政年份:
    2021
  • 负责人:
    Richard Thomas Wyatt
  • 依托单位:
国内基金
海外基金
贝莱斯芽孢杆菌TCS001对植物病原菌的广谱抑菌机理研究
  • 批准号:
    QN25C140004
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    金京
  • 依托单位:
新型大麻二酚衍生物CIAC001干预阿尔茨 海默症的靶标发现、结构优化及机制研 究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    都秀波
  • 依托单位:
1 类新药研发后补助(治疗用生物制品 1 类 SWK001 注射液、I 期临床试验)
  • 批准号:
    2025JK2100
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    胡璧梁
  • 依托单位: